Officers

Robert Preti Headshot
Chairman

Robert Preti

President & CEO,
Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector
Matt Patterson Headshot
Vice Chairman

Matt Patterson

CEO,
Audentes Therapeutics
Martha Rook Headshot
Secretary

Martha Rook

Head of Gene Editing and Novel Modalities,
MilliporeSigma / EMD Millipore
Rahul Aras Headshot
Treasurer

Rahul Aras

Co-Founder, President & CEO,
Juventas Therapeutics

Board of Directors

Zami Aberman

Chairman & Co-CEO,
Pluristem Therapeutics

Usman Azam

Chief Executive Officer,
Tmunity Therapeutics

Ron Bartek

Co-Founder and President,
Friedreich's Ataxia Research Alliance

Eduardo Bravo

Managing Director and CEO,
TiGenix

Samuele Butera

Global Cell & Gene Therapies Business Leader,
Novartis Oncology

Amy Butler

VP and GM Cell Biology,
Thermo Fisher Scientific

Sarah Creviston

Vice President & Global Head for Patient Advocacy & Public Affairs,
Shire

Deborah Dean

Executive Vice President & Chief Compliance Officer,
MiMedx

Flagg Flanagan

Chairman and CEO,
DiscGenics

Michael Hunt

Chief Financial Officer,
ReNeuron

Dena Ladd

Executive Director,
Missouri Cures

Paul Laikind

President & CEO,
ViaCyte

Bruce Levine

Founding Director, Clinical Cell and Vaccine Production Facility,
Abramson Cancer Center, University of Pennsylvania

Bill Lundberg

Senior Adviser & Head, Scientific Advisory Board,
CRISPR Therapeutics

Michael May

President & Chief Executive Officer,
Centre for Commercialization of Regenerative Medicine (CCRM)

Emile Nuwaysir

President & Chief Executive Officer,
BlueRock Therapeutics

Isabelle Riviere

Director, Cell Therapy and Cell Engineering Facility,
Memorial Sloan Kettering Cancer Center

Sanjaya Singh

Vice President and Global Head,
Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development

Donna Skerrett

Chief Medical Officer,
Mesoblast Limited

Bob Smith

SVP, Global Gene Therapy Business,
Pfizer

Joe Tarnowski

SVP, Cell and Gene Therapy Platform,
GlaxoSmithKline

Keith Thompson

Chief Executive Officer,
Cell & Gene Therapy Catapult

Gil Van Bokkelen

President & CEO,
Athersys

Phil Vanek

General Manager, Cell Therapy Growth Strategies,
GE Healthcare LIfe Sciences

Jeffrey Walsh

Chief Financial and Strategy Officer,
bluebird bio

Susan Washer

President & CEO,
AGTC

Jason Wertheim

Assistant Professor of Surgery - Organ Transplantation, Department of Surgery, Institute for BioNanotechnology in Medicine, Feinberg School of Medicine and Chemistry of Life Processes Institute,
Northwestern University

Claudia Zylberberg

Founder & CEO,
Akron Biotech

Executive Committee

Rahul Aras

Co-Founder, President & CEO,
Juventas Therapeutics

Eduardo Bravo

Managing Director and CEO,
TiGenix

Sarah Creviston

Vice President & Global Head for Patient Advocacy & Public Affairs,
Shire

Michael Hunt

Chief Financial Officer,
ReNeuron

Bill Lundberg

Senior Adviser & Head, Scientific Advisory Board,
CRISPR Therapeutics

Michael May

President & Chief Executive Officer,
Centre for Commercialization of Regenerative Medicine (CCRM)

Matt Patterson

CEO,
Audentes Therapeutics

Robert Preti

President & CEO,
Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector

Martha Rook

Head of Gene Editing and Novel Modalities,
MilliporeSigma / EMD Millipore

Phil Vanek

General Manager, Cell Therapy Growth Strategies,
GE Healthcare LIfe Sciences

Jason Wertheim

Assistant Professor of Surgery - Organ Transplantation, Department of Surgery, Institute for BioNanotechnology in Medicine, Feinberg School of Medicine and Chemistry of Life Processes Institute,
Northwestern University